I usually do not insult myself by going to the Yahoo board but as it is a cloudy Sunday morning and nobody seems to be here I gave it a try as it seems to have more international posters in various time zones and found this truly amazing idea, which borders on a stroke of genius.
IT would solve all our problems in one swift move:
ELUTEA13 hours ago
I saw a post on this message board showing how Lovaza , not generic Vascepa, continues to be the largest competitor to Vascepa due to the power of the massive marketing muscle of GSK. I couldn't agree more, and is why I've wondered why GSK hasn't bought AMRN. As a healthcare worker in the pharmaceutical industry there is ABSOLUTELY no more powerful way to switch from a previous product to the latest product than when the exact same company comes in with their exact same sales reps and details the docs to convert to the newer product...its just a natural evolution of the process vs trying to completely change a mindset. Imagine being able to capture all current Vascepa scripts, highly effectively convert the Brand and Lovaza scripts to Vascepa, and if needed also provide a generic version in those areas where generic V is present, ALL UNDER 1 ROOF. Has to be under consideration. The combination of current V scripts and Lovaza scripts, branded and generic, is already WELL OVER $1 billion. Kick in the international growth of V coming in 2021 and beyond and its a multi-billion dollar seller. 2nd best bet is a statin maker, ie AstraZeneca, Pfizer or Merck, to come out with a branded combination product. Buy strong at these lows in the $4-6 range...one of the 2 above ideas should come to fruition within 3 years.
Market Data 
Markets 
AI
